^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Chronic Myeloid Leukemia
    Drug:Bosulif (bosutinib) (Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Imatinib...and second-generation TKIs (dasatinib...nilotinib...and bosutinib...) are all appropriate options for first-line TKI therapy for patients with CP-CML across all risk scores.
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Int J Hematol
    Title:

    Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial

    Published date:
    04/13/2021
    Excerpt:
    In the phase 3 BFORE trial (Clinicaltrials.gov, NCT02130557), patients were randomized 1:1 to first-line bosutinib or imatinib 400 mg once daily….The major molecular response rate at 24 months favored bosutinib vs imatinib among Asian (63.6 vs 38.2%) and non-Asian (60.9 vs 52.6%) patients, as did the complete cytogenetic response rate by 24 months (86.7 vs 76.7%, 81.5 vs 76.3%).
    DOI:
    https://doi.org/10.1007/s12185-021-03144-4
    Trial ID:
    BFORE trial